NCT06847542 - A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD | Biotech Hunter

Enrollment

250

Participants

Timeline

Start Date

November 18, 2025

Primary Completion Date

September 12, 2028

Study Completion Date

October 12, 2028

Conditions

Neovascular Age-related Macular Degeneration

Interventions

DEVICE

Susvimo PDS Implant

Ranizumab will be administered via a PDS implant per the schedule described in the arm.

DRUG

Ranibizumab

"Participants will receive ranibizumab delivered through the PDS implant.~Participants will receive ranibizumab, 0.5 mg IVT injections as a supplemental treatment."